Hubungan Status Tekanan Darah Dengan Ketahanan Pasien COVID-19 Tahun 2021 – 2022 Di RSUD. Dr. H. Abdul Moeloek Bandar Lampung

Tasya Ratmadila Azzahra, Adrian Rival Djamil, Zulhafis Mandala, Firhat Esfandiari

Sari


Virus corona, yang menyebabkan sindrom pernapasan akut parah, adalah agen penyebab penyakit virus corona 2019 (COVID-19). Riwayat interaksi dekat dengan orang yang terinfeksi COVID-19 merupakan faktor risiko utama tertular virus. Pasien dengan kelainan bawaan, seperti tekanan darah tinggi, diabetes, atau penyakit jantung, akan sulit pulih. Tujuan penelitian adalah untuk mengetahui hubungan ketahanan pasien COVID-19 yang dirawat di RSUD Dr. H. Abdul Moeloek Bandar Lampung tahun 2021 dan 2022 dengan keadaan tekanan darahnya. Penelitian ini menggunakan metodologi cross-sectional berdasarkan metodologi sampel lengkap untuk melakukan penelitian observasional analitis. Kriteria inklusi dan eksklusi terpenuhi berdasarkan sampel yang digunakan untuk pengumpulan data tahun 2021 dan 2022. Dr. H. Abdul Moeloek dari RSUD mengawasi penelitian ini. Data statistik dianalisis menggunakan uji chi-square SPSS 26. Temuan penelitian: Mayoritas pasien COVID-19 di RSUD Dr. H. Abdul Moeloek Bandar Lampung menderita hipertensi derajat 1 (32 dari 58,1%), dengan hipertensi derajat 2 menjadi urutan kedua terbanyak (14 dari 24,6%). Berikutnya, empat pasien (atau 7% dari total) menderita hipertensi derajat 3, dan tujuh pasien (12,3% dari total) menderita hipertensi pada kadar normal tinggi. Dari seluruh rumah sakit COVID-19 di Lampung, rumah sakit Dr. H. Abdul Moeleok memiliki persentase penyintas terbanyak, yaitu 82,5%, dengan 10 pasien (17,2%) masih hidup. Nilai p-value sebesar 0,000 (<0,05) diperoleh dari temuan analisis chi-square menunjukkan adanya hubungan antara tekanan darah dan tingkat kelangsungan hidup pasien COVID-19.”


Kata Kunci


COVID-19; Hipertensi; Virus

Teks Lengkap:

PDF

Referensi


Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX, Wang QZ, et al. (2020)Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty. 2020 Mar 17;9(1).

Alek, Syahrizal. Hubungan hipertensi terhadap tingkat keparahan pasien covid-19 di rsdc wisma atlet kemayoran. 2023;8(1):43–9.

Anwar, A., K, H., As, A., I, S., W, Z., N, S., R, M., S, U., J, F., & G, A. (2018). Prevalence of Clinical Signs and Symptoms of Hypertension: A Gender and Age Based Comparison. Palliative Medicine & Care: Open Access, 5(2), 1–8. https://doi.org/10.15226/2374-8362/5/2/00155

Bonanad C, García-Blas S, Tarazona-Santabalbina F, Sanchis J, Bertomeu- González V, Fácila L, et al. (2020)The effect of age on mortality in patients with COVID-19: a meta-analysis with 611,583 subjects. J Am Med Dir Assoc. 2020 Jul 1;21(7):915–8.

Cascella, M., Rajnik, M., Aleem, A., Dulebohn, S. C., & Napoli, R. D. (2022). Features, Evaluation, and Treatment of Coronavirus (COVID-19). In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK554776/

Cascella, M., Rajnik, M., Alim, A., Dulebohn, S. C., Di Napoli, R., & Pendidikan Berkelanjutan, A. (2023). Layanan dari Perpustakaan Kedokteran Nasional.

Chen X, Hu MT W, Yang M, Ling J, Zhang Y, Deng L, et al.(2021) Risk factors for the delayed viral clearance in COVID‐19 patients. The Journal of Clinical Hypertension. 2021 Aug 1;23(8):1483.

Chen X, Zhu B, Hong W, Zeng J, He X, Chen J, et al.(2020) Associations of clinical characteristics and treatment regimens with the duration of viral RNA shedding in patients with COVID-19. Int J Infect Dis. 2020 Jun 30;98:252–60.

Clark, C. E., Martin, U., & J, sinead T. (2021). COVID-19 and hypertension : risks and management . A scienti fi c statement on behalf of the British and Irish Hypertension Society. Journal of Human Hypertension, 35, 304–307. https://doi.org/10.1038/s41371-020-00451-x

Efriza, E. (2021). COVID-19. Baiturrahmah Medical Journal, 1(1), 60–68.

Escobedo-de, J., Rasc, A., Gonz, E., Fern, E., Borja-bustamante, P., & Santill, A. (2020). Hypertension, Diabetes and Obesity, Major Risk Factors for Death in Patients with COVID-19 in Mexico. Archives of Medical Research, 52(January), 443–449.

Guan W, Liang W, Zhao Y, et al.(2020) Comorbidity and its impact on 1590 patients with COVID-19 in China/ : a. 2020;(March 2020).

Hartenian, E., Nandakumar, D., Lari, A., Ly, M., Tucker, J. M., & Glaunsinger, B. A. (2020). The molecular virology of coronaviruses. Journal of Biological Chemistry, 295(37), 12910–12934. https://doi.org/10.1074/jbc.REV120.013930

Huang S, Wang J, Liu F, Liu J, Cao G, Yang C, et al.(2020) COVID-19 Patients With Hypertension Have More Severe Disease: A Multicenter Retrospective Observational Study. Hypertension Research. 2020;43(8):824-831.

Huang X, Wei F, Hu L, Wen L, Chen K. (2020)Epidemiology and clinical characteristics of COVID-19. Arch Iran Med. 2020;23(4):268–71.

Imam, Z., Odish, F., Gill, I., O’Connor, D., Armstrong, J., Vanood, A., Ibironke, O., Hanna, A., Ranski, A., & Halalau, A. (2020). Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States. Journal of Internal Medicine, 288(4), 469–476. https://doi.org/10.1111/joim.1311

Kemenkes RI. Hipertensi Komorbid Tertinggi COVID-19 melalui siaran Pers Nomor: 109/HUMAS PMK/V/2021. In: RI K, editor. 2021.

Kemenkes. (2023). Kenali Dan Kendalikan Hipertensi, Sebelum Hipertensi Mengendalikan Kita.

Puchalska-Sarna, A., Baran, R., Kustra, M., Pop, T., Herbert, J., & Baran, J. (2022). The Level and Factors Differentiating the Physical Fitness of Adolescents Passively and Actively Resting in South-Eastern Poland—A Pilot Study. Children, 9(9), 1341. https://doi.org/10.3390/children9091341

Rezi, N. S. (2022). Hubungan Status Hipertensi Dengan Ketahanan Hidup Pasien COVID-19 di Kota Padang Tahun 2020-2021 [Diploma, Universitas Andalas]. http://scholar.unand.ac.id/103820/

Rodilla, E., López-carmona,M. D., Cortes, X., Cobos-palacios, L., Canales, S., Sáez, M. C., Escudero, S. C., Rubio-rivas, M., Manglano, J. D., Castro, S. J. F., Piqueras, N. V., Sanchis, E. M., Maria, P., Fontan, P., Oskar, J., Gamboa, M., García, A. G., Romero, V. M., Chamorro, L.T., ... Network, S.-. (2021). Impact of Arterial Stiffness on All-Cause Mortality in Patients Hospitalized With COVID-19 in Spain. March, 856–867. https://doi.org/10.1161/HYPERTENSIONAHA.120.16563

Samrah SM, Al-Mistarehi AH, Kewan T, Al-Khatib SM, Ibnian AM, Samrah RS, et al. (2021) Viral clearance course of COVID-19 outbreaks. J Multidiscip Healthc. 2021;14:555.

Sharma, A., Ahmad Farouk, I., & Lal, S. K. (2021). COVID-19: A Review on the Novel Coronavirus Disease Evolution, Transmission, Detection, Control and Prevention. Viruses, 13(2), 202. https://doi.org/10.3390/v13020202

Shereen, M. A., Khan, S., Kazmi, A., Bashir, N., & Siddique, R. (2020). COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses. Journal of Advanced Research, 24, 91–98. https://doi.org/10.1016/j.jare.2020.03.005

Wang S, Zhang Q, Wang P, Ye H, Jing X, Zhang Z, et al. (2021)Clinical features of hypertensive patients with COVID-19 compared with a normotensive group: single-center experience in China. Open Medicine. 2021 Jan 1;16(1):367.

Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. (2020) Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov- 2) outside of Wuhan, China: retrospective case series. BMJ. 2020 Feb 19;368:m606–m606.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al.(2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054–62.




DOI: https://doi.org/10.33024/jikk.v11i10.15073

Refbacks

  • Saat ini tidak ada refbacks.


##submission.copyrightStatement##

##submission.license.cc.by-nc4.footer##

Pendidikan Dokter Universitas Malahayati Lampung


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.